Mexico Antifungal Drugs Market Size & Outlook, 2026-2033
Related Markets
Mexico antifungal drugs market highlights
- The Mexico antifungal drugs market generated a revenue of USD 156.5 million in 2025 and is expected to reach USD 235.4 million by 2033.
- The Mexico market is expected to grow at a CAGR of 5.3% from 2026 to 2033.
- In terms of segment, azoles was the largest revenue generating drug class in 2025.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2025 | USD 156.5 million |
| Market revenue in 2033 | USD 235.4 million |
| Growth rate | 5.3% (CAGR from 2026 to 2033) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Mexico accounted for 0.9% of the global antifungal drugs market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Latin America, Brazil antifungal drugs market is projected to lead the regional market in terms of revenue in 2033.
- Brazil is the fastest growing regional market in Latin America and is projected to reach USD 311.6 million by 2033.
Azoles was the largest segment with a revenue share of 51.5% in 2025. Horizon Databook has segmented the Mexico antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2021 to 2033.
The Federal Commission for Protection against Sanitary Risks (COFEPRIS) is a health authority agency that regulates drugs and medical devices in Mexico and operates under the Mexican Ministry of Health.
Biologics and combination products need authorization and approval from COFEPRIS. The pharmaceutical products are approved under the General Health Law (Ley General de Salud) supplemented by Guidelines and Official Norms (NOMS).
The approval time can vary from 180 to 240 days depending on the drug. For the approval of generics, data regarding bioavailability of the drug has to be provided.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Glenmark Pharmaceuticals | View profile | 10001+ | Andheri, Maharashtra, India, Asia | http://www.glenmarkpharma.com |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | http://www.gsk.com |
| Astellas Pharma Inc | View profile | 14484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | http://www.astellas.com |
| Enzon Pharmaceuticals Inc | View profile | 1 | 20 Commerce Drive, Suite 135, Cranford, NJ, United States, 07016 | http://www.enzon.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Mexico antifungal drugs market size, by drug class, 2021-2033 (US$M)
Mexico Antifungal Drugs Market Outlook Share, 2025 & 2033 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
